Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
The FDA is beginning rulemaking to close the “adequate provision” loophole
Cagrilintide represents a novel approach to obesity management
Subscribe To Our Newsletter & Stay Updated
